Gamma-PN is under clinical development by GPN Vaccines and currently in Phase I for Streptococcal Pneumonia. According to GlobalData, Phase I drugs for Streptococcal Pneumonia have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gamma-PN’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gamma-PN vaccine is under development for the prevention of pneumonococcal sepsis caused by S. pneumoniae strain. The vaccine candidate is administered intranasally. It is an inactivated, gamma-irradiated and un-encapsulated streptococcus pneumoniae strain Rx1. It is prepared by deletion of the unmarked autolysin gene lytA and with the pneumolysin gene ply replaced with an allele encoding a non-toxic pneumolysoid (PdT) using gamma irradiation to inactivate the bacteria.
GPN Vaccines overview
GPN Vaccines, formerly GPN Vaccines, is a biotechnology company. It develops vaccine for the prevention of streptococcus pneumoniae (S. pneumonia), a bacterial pathogen. The company’s development state product includes Gamma-PN, a vaccine used for the prevention of S. pneumoniae strains. GPN Vaccines is involved in the serotype-independent pneumococcal vaccine research. The company’s vaccine is against bacterial pathogen which causes pneumonia, bacteraemia, meningitis, and otitis media, commonly known as middle ear infection. Its vaccine is used for children and adults to reduce S. pneumoniae strains. The company markets product under the brand name Gamma-PN. GPN Vaccines is headquartered in Griffith, New South Wales, Australia.
For a complete picture of Gamma-PN’s drug-specific PTSR and LoA scores, buy the report here.